Experimental Drug Active in Platinum-resistant Ovarian Cancer
Experimental Drug Active in Platinum-resistant Ovarian Cancer
Earlier this month at the annual meeting of the American Academy of Cancer Research, OCRF grantee Joyce Liu, MD, MPH presented research showing that 20% of women with platinum-resistant ovarian cancer responded to an experimental drug that targets a protein common in ovarian cancer. The small clinical trial is the first to show results from … Continued